CoChat
Sign Up
Cited by 11Liver Disease and TransplantationOrgan Transplantation Techniques and OutcomesMesenchymal stem cell research

Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis

Open access
Yu, Su Jong, Yoon, Jung-Hwan, Kim, Won, Lee, Jeong Min, Lee, Yun Bin, Cho, Yuri, Lee, Dong Hyeon, Lee, Minjong +5 more·2017·The Korean Journal of Internal Medicine
DOI 10.3904/kjim.2015.267PMC PMC5339463
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND/AIMS: Liver transplantation offers the only definite cure for cirrhosis but lacking donors is problem. Stem cell therapy is attractive in this setting. In this study, we aimed to explore the safety and efficacy of ultrasound-guided percutaneous portal transplantation of peripheral blood monocyte cell (PBMC) in cirrhotic patients. METHODS: A total of nine decompensated cirrhotic patients were randomized into three groups: group 1 (n = 3) was control group, group 2 (n = 3) received granulocyte-colony stimulating factor (G-CSF) mobilization for 3 days, and group 3 (n = 3) received G-CSF mobilized PBMCs by leukapheresis and PBMC transplantation through ultrasound-guided percutaneous portal vein puncture. Liver function and clinical features were evaluated. RESULTS: At baseline, the Child-Turcotte-Pugh and the model for end-stage liver disease scores were comparable in study groups. Compared with group 1, there was a tendency to improve liver function in group 3 at 6 months after treatment. Treatment was tolerable and no complications were encountered related to the G-CSF mobilization or percutaneous portal administration of PBMCs. Imaging studies showed patent portal veins at the end of the study period. CONCLUSIONS: Autologous PBMC transplantation through ultrasound-guided percutaneous portal vein puncture could be considered as a safe alternative treatment for decompensated cirrhotic patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3904/kjim.2015.267

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Three clinical trials that conducted mononuclear cell infusion through the portal vein revealed no statistically significant improvements in liver function, volume, or fibrosis.

    “Three clinical trials that conducted MNC infusion through the portal vein revealed no statistically significant improvements in liver function, volume, or fibrosis [50–52].”

    From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [52]

    The Results (Changes in laboratory data after treatment; page not available) report no significant reduction in CTP or MELD scores after portal PBMC transplantation, supporting the liver-function portion for this trial. The Methods (Follow-up; page not available) describe imaging for portal-vein patency, ascites, and HCC surveillance, but the paper does not report liver-volume or fibrosis outcomes. This paper alone also cannot establish the result of all three cited trials. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 38

  1. [1]Shim JH Lee HC Kim KM Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis J Hepatol 2010 52 176 182 20006394
  2. [2]Han Y Yan L Han G Controlled trials in hepatitis B virus-related decompensate liver cirrhosis: peripheral blood monocyte transplant versus granulocyte-colony-stimulating factor mobilization therapy Cytotherapy 2008 10 390 396 18574771
  3. [3]Pai M Zacharoulis D Milicevic MN Autologous infusion of expanded mobilized adult bone marrow-derived CD34+ cells into patients with alcoholic liver cirrhosis Am J Gastroenterol 2008 103 1952 1958 18637092
  4. [4]Lagasse E Connors H Al-Dhalimy M Purified hematopoietic stem cells can differentiate into hepatocytes in vivo Nat Med 2000 6 1229 1234 11062533
  5. [5]Korbling M Katz RL Khanna A Hepatocytes and epithelial cells of donor origin in recipients of peripheral-blood stem cells N Engl J Med 2002 346 738 746 11882729
  6. [6]Theise ND Nimmakayalu M Gardner R Liver from bone marrow in humans Hepatology 2000 32 11 16 10869283
  7. [7]Alison MR Poulsom R Jeffery R Hepatocytes from non-hepatic adult stem cells Nature 2000 406 257 10917519
  8. [8]Grove JE Bruscia E Krause DS Plasticity of bone marrow-derived stem cells Stem Cells 2004 22 487 500 15277695
  9. [9]Terai S Ishikawa T Omori K Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy Stem Cells 2006 24 2292 2298 16778155
  10. [10]Yannaki E Anagnostopoulos A Kapetanos D Lasting amelioration in the clinical course of decompensated alcoholic cirrhosis with boost infusions of mobilized peripheral blood stem cells Exp Hematol 2006 34 1583 1587 17046578
  11. [11]am Esch JS 2nd Knoefel WT Klein M Portal application of autologous CD133+ bone marrow cells to the liver: a novel concept to support hepatic regeneration Stem Cells 2005 23 463 470 15790766
  12. [12]Gordon MY Levicar N Pai M Characterization and clinical application of human CD34+ stem/progenitor cell populations mobilized into the blood by granulocyte colony-stimulating factor Stem Cells 2006 24 1822 1830 16556705
  13. [13]Yan L Han Y Wang J Liu J Hong L Fan D Peripheral blood monocytes from patients with HBV related decompensated liver cirrhosis can differentiate into functional hepatocytes Am J Hematol 2007 82 949 954 17724706
  14. [15]Levicar N Pai M Habib NA Long-term clinical results of autologous infusion of mobilized adult bone marrow derived CD34+ cells in patients with chronic liver disease Cell Prolif 2008 41 Suppl 1 115 125 18181952 PMC6496663
  15. [16]Kharaziha P Hellstrom PM Noorinayer B Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial Eur J Gastroenterol Hepatol 2009 21 1199 1205 19455046
  16. [17]Campard D Lysy PA Najimi M Sokal EM Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells Gastroenterology 2008 134 833 848 18243183
  17. [18]Teramoto K Asahina K Kumashiro Y Hepatocyte differentiation from embryonic stem cells and umbilical cord blood cells J Hepatobiliary Pancreat Surg 2005 12 196 202 15995807
  18. [19]Piscaglia AC Campanale M Gasbarrini A Gasbarrini G Stem cell-based therapies for liver diseases: state of the art and new perspectives Stem Cells Int 2010 2010 259461 21048845 PMC2963137
  19. [20]Margini C Vukotic R Brodosi L Bernardi M Andreone P Bone marrow derived stem cells for the treatment of endstage liver disease World J Gastroenterol 2014 20 9098 9105 25083082 PMC4112892
  20. [21]Lorenzini S Gitto S Grandini E Andreone P Bernardi M Stem cells for end stage liver disease: how far have we got? World J Gastroenterol 2008 14 4593 4599 18698672 PMC2738783
  21. [22]Fausto N Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells Hepatology 2004 39 1477 1487 15185286
  22. [23]Mallet VO Gilgenkrantz H Mobilizing stem cells to repair liver after surgery: dream or reality? J Hepatol 2005 43 754 756 16171889
  23. [24]de Wynter EA Buck D Hart C CD34+AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors Stem Cells 1998 16 387 396 9831864
  24. [25]Mizunaga Y Terai S Yamamoto N Granulocyte colony-stimulating factor and interleukin-1β are important cytokines in repair of the cirrhotic liver after bone marrow cell infusion: comparison of humans and model mice Cell Transplant 2012 21 2363 2375 22507241
  25. [26]Jin SZ Meng XW Sun X Granulocyte colony-stimulating factor enhances bone marrow mononuclear cell homing to the liver in a mouse model of acute hepatic injury Dig Dis Sci 2010 55 2805 2813 20130994
  26. [27]Picardi M De Rosa G Selleri C Spleen enlargement following recombinant human granulocyte colony-stimulating factor administration for peripheral blood stem cell mobilization Haematologica 2003 88 794 800 12857559
  27. [28]Falzetti F Aversa F Minelli O Tabilio A Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donor Lancet 1999 353 555 10028986
  28. [29]Lorenzini S Isidori A Catani L Stem cell mobilization and collection in patients with liver cirrhosis Aliment Pharmacol Ther 2008 27 932 939 18315586
  29. [30]Gaia S Smedile A Omede P Feasibility and safety of G-CSF administration to induce bone marrow-derived cells mobilization in patients with end stage liver disease J Hepatol 2006 45 13 19 16635534
  30. [31]Di Campli C Zocco MA Saulnier N Safety and efficacy profile of G-CSF therapy in patients with acute on chronic liver failure Dig Liver Dis 2007 39 1071 1076 17964871
  31. [32]Spahr L Lambert JF Rubbia-Brandt L Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial Hepatology 2008 48 221 229 18537187
  32. [33]Kisseleva T Brenner DA The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis J Hepatol 2012 56 965 972 22173163 PMC3307836
  33. [34]Lorenzini S Andreone P Regenerative medicine and liver injury: what role for bone marrow derived stem cells? Curr Stem Cell Res Ther 2007 2 83 88 18220893
  34. [35]Jang YY Collector MI Baylin SB Diehl AM Sharkis SJ Hematopoietic stem cells convert into liver cells within days without fusion Nat Cell Biol 2004 6 532 539 15133469
  35. [36]Wang X Willenbring H Akkari Y Cell fusion is the principal source of bone-marrow-derived hepatocytes Nature 2003 422 897 901 12665832
  36. [37]Sakaida I Terai S Yamamoto N Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice Hepatology 2004 40 1304 1311 15565662
  37. [38]Wang L Wang X Wang L Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells Gastroenterology 2012 143 1555 1563 e2 22902870 PMC3505224
  38. [39]Qi X Guo X Su C Clinical outcomes of the transplantation of stem cells from various human tissue sources in the management of liver cirrhosis: a systematic review and meta-analysis Curr Stem Cell Res Ther 2015 10 166 180 25391380

Cited by

Sorted by citations

Authors
Yu, S. J., Yoon, J.-H., Kim, W., Lee, J. M., Lee, Y. B., Cho, Y., Lee, D. H., Lee, M., Yoo, J.-J., Cho, E. J., Lee, J.-H., Kim, Y. J., & Kim, C. Y.
Affiliations
Seoul National University (KR)
Corresponding author
Yoon, Jung-Hwan
ORCID
Venue
The Korean Journal of Internal Medicine
Publisher
Korean Association of Internal Medicine
Published
2017-03-01
Volume
32
Issue
2
Pages
261-268
ISSN
  • 1226-3303 (ISSN-L)
  • 2005-6648
DOI
10.3904/kjim.2015.267
PMC
PMC5339463
OpenAlex
W2342037654
Cited by
11
References
1
Citations by year
2026: 1 · 2025: 2 · 2022: 5 · 2020: 1 · 2019: 1 · 2018: 1
FWCI
0.48
Type
journal article
Language
en
Open access
Licence
Locations
  • The Korean Journal of Internal Medicine (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders
  • National Research Foundation of Korea
  • Ministry of Education, Science and Technology (20100007381)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
Keywords
liver cirrhosis, decompensated cirrhosis, G-CSF mobilization, autologous cell therapy, stem cell therapy, liver function, portal vein patency
MeSH terms
Aged, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Monocytes, Portal Vein, Punctures, Ultrasonography, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Adult Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review